Sunday, June 26, 2022

Oragenics Inc. [OGEN] stock for 2,884 USD was acquired by Telling Fred

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Oragenics Inc. shares valued at $2,884 were purchased by Telling Fred on Jun 17. At $0.29 per share, Telling Fred acquired 10,084 shares. The insider’s holdings grew to 1,010,000 shares worth approximately $0.3 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Telling Fred purchased 78,673 shares, netting a total of over 22,776 in proceeds. Following the buying of shares at $0.29 each, the insider now holds 999,916 shares.

Before that, Telling Fred had added 3,500 shares to its account. In a trade valued at $1,004, the Director bought Oragenics Inc. shares for $0.29 each. Upon closing the transaction, the insider’s holdings increased to 3,500 shares, worth approximately $0.28 million.

As published in their initiating research note from BMO Capital Markets on June 14, 2022, Phillips 66 [PSX] has been an Outperform and the price target has been revised to $132. This represents a 31.43% premium over Wednesday’s closing price. As of January 31, 2022, Wells Fargo has reiterated its “an Overweight” rating for PSX. Earlier on January 31, 2022, Raymond James resumed its rating. Their recommendation was “an Outperform” for PSX stock.

Analyzing OGEN’s Price Performance

On Wednesday, Oragenics Inc. [AMEX: OGEN] rose 0.20% to $0.30. The stock’s lowest price that day was $0.28, but it reached a high of $0.31 in the same session. During the last five days, there has been a surge of approximately 1.69%. Over the course of the year, Oragenics Inc. shares have dropped approximately -32.74%. Shares of the company reached a 52-week high of $0.5899 on 01/04/22 and a 52-week low of $0.2184 on 05/12/22. A 50-day SMA is recorded $0.3127, while a 200-day SMA reached $0.4541. Nevertheless, trading volume fell to 0.26 million shares from 0.39 million shares the previous day.

Support And Resistance Levels for Oragenics Inc. (OGEN)

According to the 24-hour chart, there is a support level at 0.2840, which, if violated, would cause prices to drop to 0.2680. In the upper region, resistance lies at 0.3120. The next price resistance is at 0.3240. RSI (Relative Strength Index) is 48.32 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0015, which suggests the price will decrease in the coming days. Percent R is at 53.34%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Oragenics Inc. subject to short interest?

Stocks of Oragenics Inc. saw a sharp rise in short interest on Apr 28, 2022 jumping by 0.11 million shares to 3.07 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2022 was 2.96 million shares. A jump of 3.58% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.09 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.09.

Which companies own the most shares of Oragenics Inc. (OGEN)?

According to The Vanguard Group, Inc. filings, the company currently owns 5,017,144 shares, which is about 4.31% of the total OGEN shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 5017144.0 shares. With the completion of the sale, Sara-Bay Financial Corp.’s stake is now worth $652,638. BlackRock Fund Advisors acquire a 0.05% interest valued at $0.43 million while Geode Capital Management LLC sold a 0 stake. A total of 37,338 shares of Oragenics Inc. were sold by SSgA Funds Management, Inc. during the quarter, and 0 were sold by Northern Trust Investments, Inc. In its current portfolio, Fidelity Management & Research Co holds 155,806 shares valued at $50637.0.

In terms of Oragenics Inc. share price expectations, FactSet research, analysts set an average price target of $2.00 in the next 12 months, up nearly 566.67% from the previous closing price of $0.30. Analysts anticipate Oragenics Inc. stock to reach $2.00 by 2022, with the lowest price target being $2.00. In spite of this, 1 analysts ranked Oragenics Inc. stock as a Buy at the end of 2022.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam